BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2017 Results Presentation and Webcast
Bergen, Norway, 06 February 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib (BGB324), a first-in-class selective small molecule AXL inhibitor, as a potential cornerstone therapy for multiple cancer indications, will announce its results for the fourth quarter and full year 2017 on Tuesday, 13 February 2018.A presentation by BerGenBio’s senior management team will take place at 10.00 am CET at: Felix Konferansesenter, Bryggetorget 3, 0125 Oslo The presentation will webcast live and the link will be available at www.